Cargando…

Breast cancer: are long-term and intermittent endocrine therapies equally effective?

PURPOSE: In breast cancer (BC), the duration of endocrine adjuvant therapies (AT) has been extended continuously up to 10 years. We present an alternative explanation for the effect, which could enable shorter treatments. METHOD: The relevant literature on chemoprevention and (neo-)adjuvant therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engel, Jutta, Schubert-Fritschle, Gabriele, Emeny, Rebecca, Hölzel, Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324413/ https://www.ncbi.nlm.nih.gov/pubmed/32472445 http://dx.doi.org/10.1007/s00432-020-03264-0

Ejemplares similares

Breast cancer: emerging principles of metastasis, adjuvant and neoadjuvant treatment from cancer registry data
por: Engel, Jutta, et al.
Publicado: (2022)

Colonoscopy and polypectomy: beside age, size of polyps main factor for long-term risk of colorectal cancer in a screening population
por: Halfter, Kathrin, et al.
Publicado: (2021)

Expanding mammography screening for women aged 40–80 years: evidence from a modeling approach using real-world data
por: Hölzel, Dieter, et al.
Publicado: (2023)

Risk of metastasis in breast cancer through delay in start of primary therapy
por: Halfter, Kathrin, et al.
Publicado: (2023)

Use of Multicenter Data in a Large Cancer Registry for Evaluation of Outcome and Implementation of Novel Concepts
por: Schubert-Fritschle, Gabriele, et al.
Publicado: (2017)

Risk of contralateral second primary breast cancer according to hormone receptor status in Germany
por: Rusner, Carsten, et al.
Publicado: (2014)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
por: Kang, Yi-Kun, et al.
Publicado: (2021)

Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer
por: Huifang, Li, et al.
Publicado: (2022)

A semiparametric Bayesian proportional hazards model for interval censored data with frailty effects
por: Henschel, Volkmar, et al.
Publicado: (2009)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Rewiring of the Endocrine Network in Triple-Negative Breast Cancer
por: Li, Kaixuan, et al.
Publicado: (2022)

Evidence on Efficacy and Safety of Chinese Medicines Combined Western Medicines Treatment for Breast Cancer With Endocrine Therapy
por: Li, Lu, et al.
Publicado: (2021)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors
por: Qin, Ruoyan, et al.
Publicado: (2023)

Are contrast enhanced mammography and digital breast tomosynthesis equally effective in diagnosing patients recalled from breast cancer screening?
por: Siminiak, Natalia, et al.
Publicado: (2022)

Endocrine-disrupting chemicals and breast cancer: a meta-analysis
por: Liu, Haiyan, et al.
Publicado: (2023)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers
por: Leung, Euphemia Y., et al.
Publicado: (2017)

Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy
por: Zhou, Ying, et al.
Publicado: (2022)

Contemporaneous symptom networks and correlates during endocrine therapy among breast cancer patients: A network analysis
por: Jing, Feng, et al.
Publicado: (2023)

Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
por: Wu, Yun, et al.
Publicado: (2021)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

Metabolic Adaptations in an Endocrine-Related Breast Cancer Mouse Model Unveil Potential Markers of Tumor Response to Hormonal Therapy
por: Araújo, Rita, et al.
Publicado: (2022)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
por: Tian, Aijuan, et al.
Publicado: (2023)

Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
por: Clarke, Robert, et al.
Publicado: (2015)

Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
por: Yokomizo, Akira, et al.
Publicado: (2021)

Sulphate of Cinchona Equal to Sulphate of Quinia, in the Treatment of Intermittents
por: Faulkner, L.
Publicado: (1856)

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype
por: Wang, Yunmei, et al.
Publicado: (2020)

Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis
por: He, Tao, et al.
Publicado: (2022)

GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol
por: Vergauwen, Glenn, et al.
Publicado: (2023)

BREAst Cancer Personalised NuTrition (BREACPNT): dietary intervention in breast cancer survivors treated with endocrine therapy – a protocol for a randomised clinical trial
por: Rein, Michal Sela, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial
por: Smith, Samuel G, et al.
Publicado: (2023)

A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
por: Pina, Marta, et al.
Publicado: (2022)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
por: Fox, Emily M., et al.
Publicado: (2012)

Endocrine therapy for metastatic solid pseudopapillary neoplasm of the pancreas: A case report
por: Kornietskaya, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iteg8bcqu0vpklnaqrjeoro856